Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Silver-coated endotracheal tubes: Use of the devices to prevent ventilator-associated pneumonia should be restricted to high-risk patients until further data confirms their effectiveness, according to an editorial in the Aug. 20 issue of the Journal of the American Medical Association. Jean Chastre, M.D., of Univeriste Pierre et Marie Curie, Paris, asserts the exact benefit of silver-coated tubes remains unknown despite promising results from a study of Bard's first-in-class Agento IC silver-coated tube in ventilator-acquired pneumonia (VAP), published in the same issue of JAMA. Chastre cites a number of limitations of Bard's NASCENT trial: The study was not blinded, which may have introduced bias, and quantitative culture results from bronchoalveolar lavage may have been negatively influenced by introducing new antibiotics after the onset of symptoms but before obtaining respiratory secretions, Chastre notes. Also, the trial's enrollment was unbalanced in the proportion of patients with preexisting chronic obstructive pulmonary disease - a known risk factor for VAP - favoring the Agento IC group. The 2,003-patient NASCENT trial showed that the incidence of VAP in patients intubated for 24 hours or longer with Agento IC was 4.8%, compared to 7.5% in patients given Mallinckrodt's Hi-Lo endotracheal tube. Agento IC gained 510(k) clearance in November 2007
You may also be interested in...
Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches
Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.